Arterial infusion of combination therapy using dibutyryl adenosine 3', 5'-monophosphate and mitomycin C for nodular type of hepatocellular carcinoma non-occluding the main portal vein. In comparison with transcatheter arterial embolization.
スポンサーリンク
概要
- 論文の詳細を見る
Seventy five patients with nodular type of hepatocellular carcinoma (HCC) non-occluding the main portal vein were divided into the following groups and were compared for the prognosis : (I) administered intraarterial infusion therapy combining dibutyryl adenosine 3', 5'-monophosphate (DBcAMP) and mitomycin C (MMC) (<I>n</I>=13) ; (II) treated with transcatheter arterial embolization (TAE) (<I>n</I>=62). No marked difference was observed between two groups before treatment concerning the tumor size and the underlying clinical state confirmed by Child's method. Fifty % survival disclosed to be 21 months in both groups, whereas viewed from the tumor type of being single or multi-nodular, the median survival was as follows : 14 months (<I>n</I>=6) and 21 months (<I>n</I>=7) in group I, and 30 months (<I>n</I>=25) and 20 months (<I>n</I>=37) in group II, respectively. However, combination therapy exerted a reduced frequency of patients succumbing within one year after treatment : 1 (7.7%) as compared to 16 (25.8%) in group II.<BR> It is concluded that combination therapy with DBcAMP and MMC has an almost same salutary effect as TAE on HCC non-occluding the main portal vein.
- 財団法人 日本消化器病学会の論文
財団法人 日本消化器病学会 | 論文
- Infliximab 定期的投与にて5年8カ月ぶりに人工肛門を閉鎖し得た大腸クローン病の1例
- 魚骨の胃壁穿通による肝膿瘍の1例
- 肝幹細胞としての骨髄細胞
- 結核性リンパ節が十二指腸に穿破し, 潰瘍を形成したと思われる十二指腸結核の1例
- 消化器病(消化器内視鏡を含む)を専門とする指導者の育成システムが世界的な規模で動いている : "Train the Trainers" に参加して